Bortezomib Dendrimer Prodrug-Based Nanoparticle System

Combined Effect of Bortezomib and Menadione Sodium Bisulfite on Proteasomes of Tumor Cells: The Dramatic Decrease of Bortezomib Toxicity in a Preclinical Trial

(2018) Tatiana Astakhova et al.   Cancers

Bortezomib-based chemotherapy in mantle cell lymphoma

(2018) Simon Rule   LANCET ONCOLOGY

Adverse Event Reporting in Clinical Trials: Time to Include Duration as Well as Severity

(2017) Oliver Sartor   ONCOLOGIST

MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma

(2016) Y.-W. Qiang et al.   BLOOD

Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib

(2016) Brian B. Hasinoff et al.   Cardiovascular Toxicology

Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment

(2015) Moshe E. Gatt et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Behavioral and pharmacological characteristics of bortezomib-induced peripheral neuropathy in rats

(2015) Shota Yamamoto et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells

(2013) D. Chauhan et al.   CLINICAL CANCER RESEARCH

Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: A randomised phase II trial from the Groupe d’Etude des Lymphomes de l’Adulte (GELA)

(2012) Vincent Ribrag et al.   EUROPEAN JOURNAL OF CANCER

Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study

(2011) Ticiana B. Leal et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients

(2011) S. L. Corthals et al.   HAEMATOLOGICA

Bortezomib in patients with renal impairment

(2011) Isik Kaygusuz et al.   Hematology

Cardiotoxicity of the Anticancer Therapeutic Agent Bortezomib

(2010) Dominika Nowis et al.   AMERICAN JOURNAL OF PATHOLOGY

Acute Dyspnea From Treatment of AL Amyloidisis With Bortezomib

(2010) Abhimanyu Ghose et al.   AMERICAN JOURNAL OF THERAPEUTICS

Time to Treatment Response in Patients with Follicular Lymphoma Treated with Bortezomib Is Longer Compared with Other Histologic Subtypes

(2010) O. A. O'Connor et al.   CLINICAL CANCER RESEARCH

Bortezomib

(2009) Monique P. Curran et al.   DRUGS

Aminopeptidase inhibition as a targeted treatment strategy in myeloma

(2009) H. E. Moore et al.   MOLECULAR CANCER THERAPEUTICS

Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib

(2008) F.-T. Liu et al.   BLOOD

Bortezomib-Induced Skin Eruption

(2008) S. Sanchez-Politta et al.   DERMATOLOGY